Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aileron Therapeutics Successfully Completes First-Ever Stapled Peptide Clinical Trial

Published: Thursday, May 09, 2013
Last Updated: Thursday, May 09, 2013
Bookmark and Share
Safety and pharmacokinetics of ALRN-5281, a long-acting growth-hormone-releasing-hormone agonist, established in single-ascending dose study.

Aileron Therapeutics, Inc. announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.

“The successful translation of a Stapled Peptide drug into human subjects has long been our goal. It is an important milestone for Aileron, as well as for the rapidly emerging Stapled Peptide field as a whole,” said Joseph A. Yanchik, III, president, chief executive officer and co-founder of Aileron. “We are proud to pioneer the first clinical trial of Stapled Peptides, and we look forward to continuing our leadership in the development and eventual commercialization of this promising therapeutic class.”

The initial Phase 1 trial evaluated the safety and tolerability of single ascending doses of ALRN-5281 administered by subcutaneous injection in healthy adult subjects. Additional study objectives included the evaluation of pharmacokinetics (PK) and exploratory pharmacodynamic (PD) biomarkers of ALRN-5281. Thirty-two subjects completed the study. There were no serious adverse events, dose-limiting safety findings, or tolerability issues leading to withdrawal during the study.

“We now have clinical data showing that Aileron’s Stapled Peptides are capable of delivering a drug product profile previously believed to be out of reach with traditional peptide-based therapeutics, in particular PK attributes that support once-weekly dosing,” said Hubert C. Chen, M.D., vice president of clinical development at Aileron. “We are encouraged by the prospects of ALRN-5281 to demonstrate improved safety, efficacy, and convenience over currently available GH and GHRH injections. The results of this initial trial will guide us in optimizing dose selection and frequency for ALRN-5281 as a potential best-in-class therapy.”

Stapled Peptides are a new class of drugs with a unique set of properties that fully capitalize on 25 years of genetic research to attack drivers of complex diseases, including cancer, endocrine/metabolic disorders and inflammation. The Stapled Peptide platform locks peptides into their biologically active shape and imparts pharmaceutical stability within the body. Stapled Peptide drugs, such as ALRN-5281, are derived from natural peptides and are designed to remain in a safe and effective therapeutic range longer than traditional peptide hormones. This new class of drugs represents a fundamental scientific breakthrough as they offer the most advanced way to replicate normal human physiology to treat human disease.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
US-India Collab Finds Molecular Signatures of Severe Malaria
Study may be a significant advancement in understanding the causes of severe malaria.
Triple-Negative Breast Cancer Target Is Found
Researchers at UC Berkeley discover a target that drives cancer metabolism in triple-negative breast cancer.
Crucial Reaction for Vision Revealed
Scientists have tracked the reaction of a protein responding to light, paving the way for a new understanding of life's essential reactions.
Cancer Can Arise from Histone Mutations
A mutation that affects the proteins that package DNA—without changing the DNA itself—can cause a rare form of cancer.
Mimicking Evolution to Create Novel Proteins
A study by researchers in the Kuhlman lab offers a new route to design the 'cellular machines' needed to understand and battle diseases.
Can Gender Play A Role In Determining Cancer Treatment Choices?
MD Anderson study reveals “sex-biased” gene signatures in review of 13 cancer types.
New Autism Blood Biomarker Identified
Researchers at UT Southwestern Medical Center have identified a blood biomarker that may aid in earlier diagnosis of children with autism spectrum disorder, or ASD.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!